Bliss GVS Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Bliss GVS Pharma Ltd · Financial Result · 29 Oct 2026, 10:30 pm
Bliss GVS Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 31,337 (+28.2% YoY | +9.7% QoQ) ■ EBITDA: 8,058 (+85.3% YoY | +5.5% QoQ) ■ EBITDA Margin (%): 25.7 (+793 bps YoY | -104 bps QoQ) ■ PAT: 5,225 (+91.7% YoY | +4.3% QoQ) ■ EPS (INR): 4.81 (+89.4% YoY | +3.4% QoQ)
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. · 06 Nov 2026
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... · 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... · 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 · 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 · 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters · 29 Oct 2026
